You make great points pokey! Btw I was heading to get a
You make great points pokey! Btw I was heading to get a tooth pulled at the dentist today, and I was listening to Jim Cramer on CNBC. They were talking about Gilead buying Immunomesics. Cramer said Gilead was way overpaying and maybe showing they are in trouble and need to buy future business. That Gilead won’t make money on them until maybe 2023 which is nuts. Plus he made the comment that rings regarding the rush to buy companies with cures. He said you want to buy maintenance and not cures! So this is why companies like GNBT, with possible cures, gets no love from big pharmaceutical. Also why Altucell is still a deal with us, probably because big pharmaceutical doesn’t want a cure for type 1 diabetes. But we shouldn’t over pay for it either.
2
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Crossing Continents for Women's Healing When Chelsey Goodan, an American expert in adolescent education, made her way to Hangzhou, China, it wasn't just another stop on her world tour. No, this was her first venture into China, rallying with Zhang Xinyuan, the brains behind Vimi Wellness. For those not in the know, Vimi's been pioneering women's intimate health and...
Continue Reading
UK Government Faces Job Data Reliability Crisis The UK government has recently identified a pressing challenge in acquiring dependable jobs data essential for effective economic policy-making. This issue has arisen due to flaws in the Labor Force Survey conducted by the Office for National Statistics (ONS), which is the main instrument used to gauge the UK job market. The...
Continue Reading
HII Announces Quarterly Cash Dividend HII (NYSE: HII) has made a significant declaration that is likely to resonate well with its shareholders. Recently, the company's Board of Directors confirmed a quarterly cash dividend of $1.35 per share to be distributed on June 13, 2025. This move underscores HII's ongoing commitment to its investors, as it rewards those holding...
Continue Reading
ZTE's Global Summit 2025: Shaping a Smarter Future in Milan Milan recently hosted a significant event as ZTE Corporation, a renowned leader in integrated information and communication technology solutions, gathered industry leaders from around the world. Under the theme "Expanding Intelligence, Creating Possibilities," the event focused on the crucial aspects of AI-driven...
Continue Reading
Dr. Stelios Papadopoulos Appointed to Ovid Therapeutics Board Ovid Therapeutics Inc. (NASDAQ: OVID), an innovative biopharmaceutical company, has made headlines with the announcement of Dr. Stelios Papadopoulos joining its Board of Directors. Known for his remarkable contributions to biotechnology, Dr. Papadopoulos brings with him a wealth of experience that promises to...
Continue Reading
